<DOC>
	<DOCNO>NCT02624986</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics idasanutlin combination obinutuzumab participant relapse refractory FL DLBCL . Participants FL achieve complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) end induction therapy ( EOI ) eligible post-induction treatment obinutuzumab .</brief_summary>
	<brief_title>A Study Obinutuzumab With Idasanutlin Relapsed Refractory Follicular Lymphoma ( FL ) Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Age great equal ( &gt; /= ) 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Histologically document cluster differentiation ( CD ) 20positive Bcell lymphoma classify relapsed refractory FL DLBCL treatment least two prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody ( mAb ) appropriate treatment option exist At least one bidimensionally measurable lesion Agreement remain abstinent use adequate contraception , among woman men childbearing potential Known CD20negative status relapse progression Prior allogeneic stem cell transplantation ( SCT ) , autologous SCT within 100 day prior Day 1 Cycle 1 Current use systemic corticosteroid great ( &gt; ) 20 milligram ( mg ) prednisone per day ( equivalent ) , prior anticancer therapy include : radioimmunoconjugate within 12 week ; mAb antibodydrug conjugate within 4 week ; radiotherapy/chemotherapy/hormone therapy/targeted smallmolecule therapy within 2 week prior Day 1 Cycle 1 Requirement chronic anticoagulation Central nervous system ( CNS ) disease Active infection Positive human immunodeficiency virus ( HIV ) hepatitis B C Receipt live virus vaccine within 28 day prior Day 1 Cycle 1 Poor hematologic , renal , hepatic function Pregnant lactate woman History progressive multifocal leukoencephalopathy ( PML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>